BioNTech is partnering with Autolus to develop their #CARTcell program for solid tumors:
https://investors.biontech.de/news-releases/news-release-details/biontech-and-autolus-announce-strategic-car-t-cell-therapy
#Immunology #Immunotherapy

The target antigen of BioNTech SE's BNT211 CART is Claudin-6. I wrote about this in 2022 👇

https://www.nature.com/articles/d41591-022-00091-3